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ABSTRACT

ARTICLE HISTORY

Autoimmune polyglandular syndrome (APS) type 1 is a rare autoimmune disorder inherited in an
autosomal recessive pattern due to loss of function of the AIRE gene and defective removal of selfreactive T-lymphocytes during the process of thymic T cell maturation. Its manifestation starts early
in life with the cardinal clinical disorders being one of muco-cutaneous candidiasis, Addison’s
disease, and hypoparathyroidism. Recognizing the syndromic nature of one autoimmune disease
will facilitate an active search for other conditions which would allow early detection, management,
follow-up, and most importantly patient education and counselling to avoid potential complications. We present the case of a young immigrant with multiple endocrinopathies and mucocutaneous candidiasis who presented with features of adrenal insufficiency. Our aim was to briefly
review APS type 1 as a disease entity and to highlight the importance of patient education in its
management.
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1. Introduction
Autoimmune polyglandular syndrome (APS) type 1, also
known as autoimmune polyendocrinopathy-candidiasisectodermal dystrophy/dysplasia (APECED) [1] or
Whitaker syndrome [2], is defined as the presence of
two or more of the following: Addison’s disease, chronic
muco-cutaneous candidiasis, and hypoparathyroidism
[3]. It occurs in childhood with 1:1 male to female ratio,
inherited in an autosomal recessive pattern, and has an
incidence of about 3/1,000,000 people. Although treatment is identical whether it occurs in isolation or as part
of an APS, clinicians must be alert to syndromic associations of autoimmune diseases to prevent delayed
diagnosis.

2. Case report
A 29-year-old man with past medical history of
Addison’s disease and hypothyroidism who recently
relocated to the USA from Puerto Rico presented to
the emergency department (ED) with chief complaints of fatigue, palpitations, and light headedness.
He was previously maintained on twice daily
hydrocortisone and daily levothyroxine supplementation but had been off his medications for 5 days. He
denied chest pain or shortness of breath. He also
denied tremors, easy fatigability, weight gain, hoarseness of voice, or changes in bowel habit. Of note, he
reported a childhood history of recurrent seizures
due to hypocalcemia and had since been on calcium
and vitamin D supplementation. He had no family
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history of autoimmune disease and review of systems
was otherwise unremarkable. His knowledge about
his medical condition was limited.
On physical examination, he was in no acute distress. He was hypotensive with BP 89/67 and tachycardic with pulse rate of 115 bpm. Other vital signs
were normal. Chvostek sign was negative and there
was no thyromegaly on neck palpation. Oral examination showed multiple hyperpigmented lesions on
the dorsum of his tongue (Figure 1) and multiple
deformed and pitting finger nails in both hands
(Figure 2). The remainder of the physical examination was unremarkable.
Basic metabolic panel revealed hyponatremia with
Na 129 meq/L (136–145) and potassium of 4.8 meq/L
(3.5–5.1). He was also severely hypocalcemia with
ionized calcium of 0.96 mmol/L (1.15–1.33). Fasting
blood glucose was normal. Thyroid function test
showed elevated thyrotropin level at 5.807 uIU/mL
(0.450–5.330) with normal free thyroxine level at 0.94
ng/dL (0.58–1.64). AM cortisol was markedly reduced
at <1 mcg/dL (6.7–22.6). ACTH was markedly elevated
at 785 pg/mL (7–69) and direct renin was also very
elevated at 390 pg/mL (2.5–45.7). Parathyroid hormone
was markedly reduced at <6 pg/mL (12–88). Complete
blood count was normal, as was coagulation profile.
ECG also showed sinus tachycardia with no
ischemic changes.
The patient was given intravenous saline and double his normal dose of his steroids. His levothyroxine
dose was continued at 75 mcg daily while intravenous
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discharged home on hydrocortisone 20 mg in the
morning and 10 mg at night with fludrocortisone
0.1 mg daily and levothyroxine 75 mcg daily.
On follow-up in clinic 2 weeks later, patient was
noted to be doing well. Patient education regarding
medication adherence and stress dosing to avoid
potentially life-threatening adrenal crisis and the
importance of medic alert bracelets was reinforced.
The patient was classified as having APS type 1
because of the presence of hypoparathyroidism,
Addison’s disease, and chronic muco-cutaneous candidiasis, and promptly referred to the endocrinologist
for continuity of care (Figure 3).

Figure 1. Showing oral candidiasis.

3. Discussion

Figure 2. The finger nail changes.

APS type 1 occurs due to loss of function of the autoimmune regulator gene – AIRE (AI – autoimmune,
RE – regulator) gene, located on chromosome 21 particularly expressed in the thymus gland which plays an
important role in immune regulation by distinguishing
self from non-self. The result is the formation of autoantibodies directed against specific tissue [4–6].
APS type 1 is almost always inherited as autosomal
recessive with both set of AIRE genes affected, although
cases of autosomal dominant mutation in AIRE have
been described [5] and the disease spectrum is much
more narrow than in the recessive type [6].
Other less frequent autoimmune diseases occurring in association with this condition include type
1 diabetes mellitus, vitiligo, pernicious anemia, primary hypothyroidism, hypergonadotropic hypogonadism (primary hypogonadism), pituitary failure,
autoimmune hepatitis, alopecia, interstitial nephritis,
malabsorption syndrome, splenic aplasia or hypoplasia, and pure red cell aplasia [5,7].
Onset typically begins in childhood with multiple
autoimmune disorders manifesting throughout
patient’s lifetime [8]. In most cases, the first symptom is a chronic mucocutaneous candidiasis even
before the development of endocrine disorders and
usually affects the oral cavity, esophagus, and the
skin. It is the most common manifestation of APS
type 1 and is seen in almost 100% of cases [5].
The cause of muco-cutaneous candidiasis in
these patients, a hallmark of the disease, was initially
unknown and not attributed to autoimmune dysfunction [4]. More recent studies found that the
disruption of the T helper-17 cell (Th-17)-based
adaptive immunity to fungal infection is responsible
for the chronic mucocutaneous candidiasis (CMC)
[9]. Patients with APS type1 produce autoantibodies
against specific Th-17 cells cytokines mainly IL17A,
IL-17F, and IL-22 thus disrupting the innate antifungal immunity [9,10].

Figure 3. Timing of major clinical features in APS type 1.

and oral calcium were given to correct hypocalcemia.
His symptoms gradually improved, and he was
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Hypoparathyroidism is usually the first endocrine
disorder to manifest during the course of the disease
and has been reported in about 70–93% of cases.
Addison’s disease has a prevalence of about 60–
100% [5]. Timing of the major clinical features is
illustrated in the table below. Other clinical presentation may include fatigue due to pernicious anemia,
enamel hypoplasia, dystrophic nails, diarrhea, and
cholelithiasis from malabsorption syndrome, and
abnormal liver enzymes in autoimmune hepatitis
[11]. Apart from the more common cutaneous associations, a rare case of acquired generalized lipodystrophy has been associated with APS type1 [12].
Diagnosis of APS type 1 is largely based on the
measurement of serum endocrine and organ-specific
autoantibody in patients presenting with clinical history suggestive of one or more endocrine disorder
and (or) chronic mucocutaneous candidiasis.
A definitive diagnosis can be made through DNA
analysis for AIRE gene mutation [13], and this may
be of benefit in patients who do not meet the diagnostic criteria of APS type 1 at initial presentation
[14]. The finding of one organ-specific autoimmune
disorder should prompt further evaluation for other
associations.
The mainstay of treatment remains hormone
replacement and systemic antifungal therapy.
Correction of deficient electrolytes such as calcium
and sodium may be required. Immunosuppressive
therapy has been used with variable success rates.
Routine monitoring and investigation of patient for
upper gastrointestinal symptoms as risk of oral/esophageal squamous cell carcinoma (SCC) increases.

4. Conclusion
In summary, this case highlights the need for high
index of suspicion for APS and judicious search for
other autoimmune conditions whenever one organspecific autoimmune disorder is diagnosed. Longterm monitoring of patients with autoimmune disorders is important because the time interval before the
appearance of other endocrine disorders cannot be
predicted. Given how common chronic mucocutaneous candidiasis is as well as its early manifestation, routine evaluation is advised to detect any oral
or esophageal SCC. Also, the importance of patient
education cannot be over-emphasized.
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